Cariuk P, Lorite M J, Todorov P T, Field W N, Wigmore S J, Tisdale M J
Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.
Br J Cancer. 1997;76(5):606-13. doi: 10.1038/bjc.1997.433.
Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month(-1)). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200,000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of M(r) 24,000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice.
体重减轻的癌症患者尿液中存在一种分子量为24,000的抗原,该抗原可被一种单克隆抗体检测到,该单克隆抗体由患癌恶病质小鼠的脾细胞融合形成。正常受试者、因癌症以外的其他疾病导致体重减轻的患者或体重稳定或体重减轻较少(每月1 kg)的癌症患者尿液中不存在该抗原。胰腺、乳腺、肺和卵巢癌患者的尿液中存在该抗原。使用与小鼠单克隆抗体结合的亲和色谱法和反相高效液相色谱法(HPLC)从尿液中纯化该抗原。该方法使蛋白质的纯化程度比原始尿液提取物提高了200,000倍,通过凝胶银染测定,分离得到的物质是均一的。N端氨基酸序列与任何已知的细胞因子均无同源性。与接受从正常受试者尿液中以相同方式纯化的物质的对照组相比,给小鼠注射该物质会导致体重显著减轻(P<0.005)。体重减轻时食物和水的摄入量并未减少,预先注射小鼠单克隆抗体可预防体重减轻。身体成分分析显示脂肪和非脂肪胴体质量均减少,而含水量没有变化。用单克隆抗体处理的小鼠中,对身体成分的影响得到逆转。骨骼肌中蛋白质合成减少,降解增加。蛋白质降解与前列腺素E2(PGE2)释放增加有关。预先用单克隆抗体处理的小鼠中,蛋白质降解和PGE2释放均显著减少。这些结果表明,恶病质癌症患者尿液中存在的分子量为24,000的物质能够在小鼠中产生恶病质综合征。